Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor α inhibitors

Pedersen, Susanne Juhl; Sørensen, Inge Juul; Hermann, Kay-Geert A.; Madsen, Ole Rintek; Tvede, N.; Hansen, Michael Sejer; Thamsborg, Gorm; Andersen, Lis Smedegaard; Majgaard, Ole; Loft, Anne Gitte; Erlendsson, Jon; Asmussen, Karsten; Johansen, Julia S.; Jurik, Anne Grethe; Møller, Jakob M.; Hasselquist, Maria; Mikkelsen, Dorrit; Skjødt, Thomas; Hansen, Annette; Østergaard, Mikkel

doi:10.1136/ard.2009.111187

Cited by 110 publications

(74 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it was stated that ASDAS showed better correlation and higher discriminative ability than BASDAI in patients with AS [11]. Several studies showed that ASDAS is reliable and reproducible and in some cases better than BASDAI [12,13]. Although it is difficult to calculate without using a calculator [9,11], the availability of desktop and smartphone calculators for ASDAS has lessen this problem considerably.…”

Section: Introductionmentioning

confidence: 95%

A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis

et al. 2015

View full text Add to dashboard Cite

A single questionnaire regarding to disease activity for all rheumatic diseases may present advantages to introduce quantitative measurement into routine care. The aim of this study was to evaluate the correlation of routine assessment of patient index data 3 (RAPID3) with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS). A total of 341 consecutive AS patients who met the modified New York classification criteria were included. All patients completed BASDAI and RAPID3 at each visit, and their physicians completed physician global assessment. ASDASs were calculated using defined formulas. Proposed RAPID3 severity categories were compared to BASDAI and ASDAS categories. Spearman's rho correlation test and kappa statistics were used to analyze statistical significance. The median age of AS patients was 34.0 (21.0-69.0) years and the median disease duration 10.0 (2.0-35.0) years. Median scores for RAPID3, BASDAI, ASDAS-CRP, and ASDAS-ESR were 13.0 (0.0-27.3), 4.7 (0.0-9.7), 3.0 (0.4-5.8), and 2.5 (0.5-6.3), respectively. RAPID3 was strongly correlated with BASDAI and ASDAS-ESR (r = 0.842, r = 0.815; p < 0.001, respectively). Among the 209 patients with high disease activity according to BASDAI, 83.3 % had high or moderate severity according to RAPID3 (kappa 0.693; p < 0.001). Among the 133 patients with moderate, high, and very high disease activity on ASDAS-CRP, 91.7 % had high or moderate severity according to RAPID3 (kappa 0.548; p < 0.001). RAPID3 is as informative as BASDAI and ASDAS in our cohort of AS patients. We therefore suggest that RAPID3 may be used to assess the patient status quantitatively in AS patients, as part of routine care.

show abstract

Section: Introductionmentioning

confidence: 95%

A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the initial studies of adult patients with IBP of less than 2 years, these diagnostic and classificatory properties of both the ASAS axial and peripheral SpA criteria appear to be better than those of reported by Amor, et al [37] and ESSG [38] groups and implementation is under way. Drug efficacy studies are being carried out in patients with axial SpA to determine the role of TNF blockers in remission and prevention of structural damage [71-73]. …”

Section: Reviewmentioning

confidence: 99%

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist

Burgos‐Vargas

2012

Pediatr Rheumatol

View full text Add to dashboard Cite

This review refers to the origin and current state of the assessment of the SpondyloArthritis International Society (ASAS) criteria for the classification of axial and peripheral spondyloarthritis (SpA) and the possible implications in the pediatric population. The ASAS criteria evolved from the idea that the earlier the recognition of patients with ankylosing spondylitis, the better the efficacy of tumor necrosis factor blockers. Strategies included the development of new concepts, definitions, and techniques for the study of clinical signs and symptoms. Of relevance, the new definition of inflammatory back pain (IBP) and the introduction of sacroiliitis by magnetic resonance imaging represented the most important advance in the early identification of AS in the “pre-radiographic stage” of the disease. AS is considered in this paper as a disease continuum with symptoms depending on age at onset. The application of those specific strategies in children and adolescents with SpA seems limited because the most important manifestation in the early stage of disease is not IBP, but peripheral arthritis and enthesitis. In this instance, the logical approach to juvenile onset SpA according to ASAS criteria should not be through the axial criteria but rather the peripheral set of criteria.

show abstract

“…Therefore, it would be beneficial to identify biomarkers of inflammation that accurately reflect the findings of MRI in axSpA patients. CRP levels show a moderate correlation with MRI inflammation scores [33], but the results are inconsistent [35,36]. Recent studies identified new biomarkers of inflammation, including markers of angiogenesis and tissue turnover.…”

Section: Discussionmentioning

confidence: 99%

Platelet Indices Are Associated with Disease Activity Scores and the Severity of Sacroiliitis on Magnetic Resonance Imaging in Axial Spondyloarthritis Patients

et al. 2016

View full text Add to dashboard Cite

Objective. To investigate the associations among platelet indices, disease activity scores, and inflammatory markers in axial spondyloarthritis, and to determine the relation between platelet indices and inflammation measured on magnetic resonance imaging (MRI). Methods. The study included 161 patients who fulfilled Assessment of Spondyloarthritis International Society criteria. Platelet indices such as mean platelet volume (MPV), plateletcrit (PCT), platelet large cell ratio (PLCR), and platelet distribution width (PDW) were measured. Ninety patients underwent sacroiliac (SI) MRI at baseline. Bone marrow edema (BME) and erosion on MRI were scored using the SPondyloArthritis Research Consortium of Canada (SPARCC) method. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS) and spinal radiologic progression were also assessed. The associations among platelet indices and disease activity scores and inflammatory markers were evaluated. Results. Of the 161 patients, 130 (81%) were male. MPV, PLCR, and PDW were negatively associated with ASDAS and inflammatory marker expression, whereas PCT was positively associated with these parameters. MPV, PLCR, and PDW were negatively associated with BME and erosion scores on SI MRI. However, platelet indices were not associated with the BASDAI and BASFI. The mean erythrocyte sedimentation rate, C-reactive protein, and BME and erosion scores were significantly higher in patients with low MPV. Changes in MPV, PCT, and PDW at baseline and after one year were associated with changes in ASDAS and inflammatory marker expression. Conclusion. Platelet indices are associated with ASDAS, inflammatory marker levels, and severity of BME and erosion measured on MRI. (J Rheum Dis 2016;23:288-296)

show abstract

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor α inhibitors

Abstract: ASDAS demonstrates construct validity and high responsiveness during treatment with TNFalpha inhibitors in patients with SpA. The proposed thresholds for disease activity and treatment response need further validation. Trial registration number NCT00133315.

Cited by 110 publications

References 26 publications

A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis

A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist

Platelet Indices Are Associated with Disease Activity Scores and the Severity of Sacroiliitis on Magnetic Resonance Imaging in Axial Spondyloarthritis Patients

Contact Info

Product

Resources

About